In the ever-evolving world of oncology, the intersection of artificial intelligence (AI) and precision medicine shines as a beacon of hope for countless individuals battling cancer. But can AI transform the way oncologists treat patients?
Mark your calendars for an engaging webinar on August 30th, 2023, at 6:00 PM (EEST), as Genomate teams up with DrugBank to unravel the profound impact of AI on Precision Oncology. This webinar will provide clarity and a better understanding of the transformative potential of AI in cancer detection, treatment identification, and holistic patient care.
Guided by Chris Klinger, Scientific Support Lead at DrugBank, this webinar will feature a distinguished panel of experts from Genomate's team:
- Barbara Vodicska, Head of Translational Science at Genomate Health Inc
- Istvan Petak, CEO & Founder of Genomate Health Inc
- Robert Doczi, Head of Research at Genomate Health Inc
- Sean Khozin, Advisor on Medical Affairs and Regulatory Strategy at Genomate Health Inc
Together, they will delve into AI's profound impact on revolutionizing Precision Oncology's landscape. This webinar is an unmissable opportunity for those interested in the intersection of AI and healthcare. As precision medicine gains traction as the new norm, comprehending the pivotal role of AI becomes paramount. Whether you're a seasoned oncologist, a researcher, or an individual intrigued by how technology is reshaping cancer care, this dialogue promises invaluable insights.
As precision medicine continues its ascendancy, grasping the pivotal role of AI becomes indispensable. This discussion is an unparalleled opportunity to glean invaluable insights for oncologists, researchers, and individuals keen on understanding the dynamic fusion of technology and medical science. The importance of this conversation is not just limited to the medical community; for patients and caregivers, it signifies a beacon of hope—a future where treatment is tailored to individual needs, thereby enhancing the likelihood of success.
Dr. Istvan Petak, CEO & Founder of Genomate Health Inc, aptly encapsulates the significance of this intersection: "The nexus of biology, technology, and AI is where the future of oncology lies." With Genomate's revolutionary approach, patients benefit from treatment options intricately woven with their unique tumor profiles.
Genomate's AI-powered clinical decision support system analyzes the patient's molecular profile, including all their cancer cells' genetic alterations. By analyzing the patient's complete molecular profile, Genomate provides an in-depth report highlighting the most effective targeted therapies tailored to address the specific genetic drivers of the patient's cancer. Based on the cumulative score, the report helps the oncologist prioritize the driver genes to target and the best drugs to do it with. Armed with Genomate's comprehensive report, the oncologist gains valuable insights into the totality of the patient's genetic alterations. With the ability to rank the strength of different driver genes, the oncologist can prioritize the most impactful treatment options, ensuring the patient receives the best possible care.
We invite you to join our worthy panel in this exciting webinar. Bring your questions, curiosity, and enthusiasm to plunge into the realm of AI in precision oncology. Discover the future of cancer care and sign up to participate in the webinar by visiting the webinar registration link.
About our team
Barbara Vodicska, PhD, is a trained biochemical engineer with expertise in studying the molecular background of prion diseases and cancer. She completed her doctoral research at the German Cancer Research Center (DKFZ) in Heidelberg. Currently, she holds the position of Head of Translational Science at Genomate Health, where she contributes to research and development efforts focused on a software as a medical device. This revolutionary software aims to improve targeted therapy decisions in the field of precision oncology.
Istvan Petak, MD, PhD, is an expert in precision oncology and molecular pharmacology of targeted therapies with 25+ years of experience. He is the founder and CEO of Genomate Health, Inc., founder and board director of Oncompass Medicine, Budapest, HU, and adjunct professor at the Department of Pharmaceutical Sciences at the University of Illinois at Chicago (UIC).
Robert Doczi, PhD is a molecular biologist with over 20 years’ experience in cellular signaling. He is currently Head of Research at Genomate Health, where he is involved in the development and clinical validation of a novel computational method that implements cognitive computing in precision oncology. Previously he was a postdoctoral researcher at Vienna Biocenter (Austria) and was a Marie Curie Fellow at Royal Holloway, University of London (UK) and, before joining the company, he was a principal investigator at the Hungarian Academy of Sciences.
Sean Khozin, MD, MPH, is a globally recognized oncologist, data scientist, and physician-executive with extensive experience in therapeutic development and AI applications in biomedical research. As the founder of Phyusion and Senior Partner at Braven, he focuses on advancing innovations at the nexus of biology, technology, and AI. Previously, he was the CEO of CancerLinQ, the Global Head of Data Strategy at Johnson & Johnson, and a founding member of the US FDA’s Oncology Center of Excellence in addition to serving as the founding executive director of INFORMED, FDA’s first science and technology incubator. Dr. Khozin is the cofounder of the technology company Hello Health and founder of SKMD, a multidisciplinary network of clinics utilizing telemedicine and remote monitoring tools to improve patient outcomes. He is a Research Affiliate at MIT and started his clinical research work at the US National Cancer Institute developing molecular profiling strategies in thoracic malignancies.
About Genomate Health
Genomate Health Inc. is a digital health company (based in Cambridge, MA) that develops AI-powered computational tools for personalized medicine. Its main focus is assisting physicians in making optimal personalized treatment decisions for each patient based on the complex molecular characteristics of human diseases.
Its flagship product, Genomate® MTC (Molecular Treatment Calculator), is a powerful computational (open box AI) tool aiming to optimize treatment decision-making in precision oncology by automated data compilation, evaluation, and synthesis in a knowledge model allowing standardized, personalized treatment decisions based on the totality of available molecular information. The company’s goal is to make this solution globally available to cancer patients and their oncologists in 2023. For more information, visit www.genomate.health, and follow the momentum on Facebook, Twitter, Instagram, and LinkedIn.
DrugBank is the world’s first intelligent and comprehensive drug knowledge platform. Utilizing artificial intelligence, their team of experts gather, author, verify, and structure the latest biomedical information into one knowledge platform. This platform is accessible through DrugBank Online (their free-to-use website), and data and software integrations. DrugBank is honoured to partner with the world’s leading biomedical researchers as they pursue their goal of better medical outcomes. www.drugbank.com
Brand Manager, Genomate Health Inc